Evanium Healthcare, a German biotech firm, has secured a significant investment in a new financing round. The funding was led by prominent venture capital firms FoodLabs and Feast Ventures. This capital injection is earmarked to advance its proprietary OPTISOLV® technology, which aims to solve the critical issue of low bioavailability in nutritional supplements.
Addressing a Core Industry Challenge
The nutritional supplement market often struggles with a fundamental efficacy problem despite premium pricing. Many active ingredients are poorly absorbed by the human body, diminishing their intended health benefits. Evanium's technology directly confronts this widespread issue by fundamentally improving how these compounds are utilized.
The Science Behind OPTISOLV®
At the core of Evanium's innovation is the OPTISOLV® platform, a unique dual-coating delivery system. It combines a cyclodextrin-based core with an outer phospholipid shell to encapsulate natural active ingredients. This structure stabilizes the compounds in a crystal-free, highly dispersible state, preventing agglomeration and enhancing permeability.
The technology's impact is demonstrated with challenging compounds like curcumin, showing remarkable performance gains. Its solubility increases by over 1,000 times compared to its native form, while its release during digestion improves by more than 170 times. These results show that OPTISOLV® significantly outperforms conventional phospholipid-based delivery methods in direct comparative tests.
Strategic Growth and Market Validation
The new funding will fuel a multi-faceted growth strategy for the Regensburg-based company. Resources will be allocated to expand the scope of clinical trials, further validating the efficacy of its formulations. The investment also supports the diversification of its product portfolio and accelerates its planned international market expansion.
Evanium has already established a strong market presence and proven its industrial capabilities. In 2025, the company successfully launched OPTISOLV® Curcumin in partnership with Hevert Arzneimittel, a leading German manufacturer. Furthermore, the company demonstrated its production maturity by delivering over two tons of material in 2026 alone.
Company Origins and Vision
Founded in 2019 at BioPark Regensburg, Evanium was established by a multidisciplinary team with expertise in pharmacy and entrepreneurship. The company has rapidly transitioned from a research-focused startup into a key technology partner for established industry players. Now employing a team of twelve, it continues to build on its foundational vision of enhancing natural ingredients.
This successful financing round marks a pivotal moment for Evanium Healthcare, validating its innovative approach to supplement efficacy. With fresh capital and proven technology, the company is well-positioned to redefine industry standards for bioavailability. The expansion of its OPTISOLV® platform promises to deliver more effective nutritional products to consumers worldwide.